NVO

Novo Nordisk A/S Common Stock (NVO)

Stock · NYSE · Health Care

$45.6as of 8/28/2026

AI Market Commentary

AI-generated

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

August 30, 2026

Novo Nordisk Draws Renewed Attention After Two Recent Analyst Notes. Two analyst notes on Novo Nordisk were published over the past week. One commentator described the stock as a "dirt-cheap buying opportunity," citing valuation as a key point. Separately, a separate article highlighted significant whale-alert trading activity in today's session, indicating large institutional moves in the name. Taken together, the coverage reflects renewed market focus on Novo Nordisk, though the articles do not agree on whether recent price weakness reflects a concern or an opening.

Active signals

Support level
$43.77
Industry
Biotechnology: Pharmaceutical Preparations

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare b…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Employees
66,700

Fundamentals

1-day range
$45.41$46.21
Market cap
$203.55B
P/E (trailing)
11.40
P/E (forward)
13.30
EPS (trailing)
$26.18
Dividend yield
1.00%
Beta
1.92
Avg. volume
12.39M
Ex-dividend date
August 17, 2026
Dividend pay date
August 25, 2026
52-week range
$224.25$409.95
Next earnings: November 4, 2026 · EPS estimate $5.14confirmed

Forecasts

12 analyst ratings

Buy 35%
Hold 60%
Sell 5%
1-year price forecast
High
$63.96
+40.3%
Median
$45.09
-1.1%
Low
$40.14
-12.0%

Novo Nordisk A/S Common Stock Competitors

Chosen by industry and closest market cap.

  • NVO
    Novo Nordisk A/S Common Stock
    $45.6
    ▼ 1.43%
    Market cap $203.55BP/E 11.40
    $224.25$409.95
  • ABT
    Abbott Laboratories Common Stock
    $112.42
    ▲ 0.74%
    Market cap $186.81BP/E 35.52
    $81.97$137.49
  • AZN
    AstraZeneca PLC Ordinary Shares
    $162.69
    ▼ 1.11%
    Market cap $249.78BP/E 23.44
    $10,784$15,730
  • PFE
    Pfizer Inc. Common Stock
    $27.95
    ▼ 0.25%
    Market cap $149.33BP/E 35.19
    $23.58$28.75
  • VRTX
    Vertex Pharmaceuticals Incorporated Common Stock
    $541.72
    ▼ 1.06%
    Market cap $122.68BP/E 30.70
    $374.17$555.69
  • NVS
    Novartis AG Common Stock
    $153.79
    ▼ 0.56%
    Market cap $294.26BP/E 21.95
    $96.03$131.5
  • GSK
    GSK plc American Depositary Shares (Each representing two Ordinary Shares)
    $50.82
    ▲ 1.09%
    Market cap $105.65BP/E 15.53
    $1,441$2,282

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
403.38M
Total value held
$14.15B
Institutional holders
1272
Top holders this quarter
  • Unknown31.02M
  • Unknown20.14M
  • Unknown19.33M
  • Unknown17.02M
  • Unknown16.08M
  • Unknown12.88M
  • Unknown11.80M
  • Unknown11.06M
  • Unknown10.87M
  • Unknown10.77M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.